. 2022 Jan 19;147:112650. doi: 10.1016/j.biopha.2022.112650

Table 4.

Immunogenicity in different variants of concern in reported studies.

Study	Type of vaccine	Outcomes	Type of variant
Hillus[23]	ChAd/BNT	The Geometric mean of 50% inhibitory dose (95% CI)	α (B.1.1.7)	β (B,1.351)	γ (B.1.1.28.1)	δ (B.1.617.2)
	ChAd/BNT		956.6 (835.6–1095)	417.1 (349.3–498.2)	NA	NA
	ChAd/ChAd		212.5 (131.2–344.4)	48.5 (28.4–82.8)
	BNT/BNT		369.2 (310.7–438.6)	72.4 (60.5–86.5)
Groβ[24]	ChAd/BNT	Neutralizing activities median titer of serum samples	2744 (209.8–8985)	1297 (252–6523)	NA	1309 (150–13,252)
Groβ[24]	BNT/BNT	Compared to ChAd/BNT group	Lower ( p < 0.001)	Lower ( p < 0.05)	NA	Lower (not significant)
Barros[30]	ChAd/BNT	Neutralization capacity of Ab	All participants	All participants	All but two participants	NA
Barros[30]	ChAd/ChAd		Increased in some individuals	No effect	No effect	NA
Behrens[31]	ChAd/BNTWith ChAd/ChAd	50% neutralization titers (NT₅₀)	ChAD/BNT induced higher levels against all type of variants compared to ChAd/ChAd group.NT₅₀ ≥ 100 in 85% of vaccines in delta variant
Hammeschmidt[20]	ChAd/BNT with ChAd/ChAd	Surrogate virus neutralization tests	NA	NA	NA	ChAd/BNT vaccination induced ninefold increase in neutralizing titers compared to ChAd/ ChAd group.
Fabricius[35]	ChAd/mRNA	Mean neutralization capacity individuals	87%	85%	71%	NA
	mRNA/mRNA		76%	73%	56%
	ChAd/ChAd		48%	57%	15%
Normark[29]	ChAd/mRNA	Neutralizing Ab		Induced Ab could neutralize the β variant
Normark[29]	ChAd/ChAd			Did not induce potent Ab against this variant
Kant[25]	ChAd/covaxin	Geometric mean titers with 95% confidence interval (CI)	396.1 (199.1–788)	151 (80.21–284.3)	NA	241.2 (74.99–775.9)
	ChAd/ChAd		122.7 (59.36–253.7)	48.43 (19.71–119)		51.99 (19.65–137.6)
	Covaxin/Covaxin		112.4 (76.56–164.9)	52.09 (34.9–77.73)		54.37 (27.26–108.4)

NA: Not available; CI: confidence interval